Welcome, visitor! [ Login

Dragon Reports 2003 Third Quarter Results


Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and nine-month periods ended September 30, 2003. During the quarter, the Company posted revenues of $1,151,646 from the sales of rHu Erythropoietin (EPO), which is currently marketed for the treatment of anemia related to chronic renal failure and for surgery patients in China, India, Egypt, Peru and Brazil. Of the $1,151,646 in revenues during quarter ended September 30, 2003, $742,467 were generated from sales in China and $409,179 from sales in other countries. Quarter revenues for the prior year were $3,777,326 consisting of $745,326 of sales in China and $3,032,000 in sales outside of China including a one-time order of $3,000,000, in 2002.

Operating expenses for the third quarter of 2003 were $1.08 million, down from $1.72 million for the same period in 2002, reflecting the results of our continued efforts to tighten control of expenses. Net loss for the third quarter of 2003 was $282,582, or $0.01 per share compared to a net profit of $1.6 million, or $0.08 for the third quarter of 2002. As discussed previously, revenues for the third quarter of 2002 included a one-time EPO bulk sale of $3 million.

For the 9-months ended September 30, 2003 revenues were $2.8 million down from $6.2 million for the same period in 2002, which included a $3.7 million one-time order of bulk EPO. Operating expenses were reduced to $3.2 million for the 9-month period in 2003 compared to $6.6 million for the same period in 2002. Net loss for the 9-month period in 2003 was $1.25 million, or $0.06 per share, compared to $1.14 million, or $0.06 per share for the same period in 2002.

“The Company has managed to achieve sequential improvement in sales and continued efforts to tighten control of expenses. As a result, the net loss per share for the nine months ended September 30, 2003, was approximately the same as the prior period in 2002 which included a one-time order of $3.7 million. However, we are disappointed that we are unlikely to achieve the break-even point this year due to intense competition in certain markets driving down the average price of our products and the delay of decision by certain customers on bulk purchases,” stated Dr. Alexander Wick, President and Chief Executive Officer of Dragon Pharmaceutical Inc. “Given that we have significantly improved our cost structure and reduced the operating expenses, the Company believes that the net loss for the full year ending December 31, 2003 will be significantly less than last year.”

Further, the Company also announced that as previously reported, in 2002, Dr. Longbin Liu, a director of the Company, exercised his right to repurchase the Company’s Hepatitis B vaccine project for the original purchase price of $4 million, of which $500,000 has been paid and the balance of $3.5 million plus interest was due during the third quarter 2003 but remained unpaid. “The Company does not see any significant financial impact of this event on the 2003 results because the Company had chosen to write off such balance in the fourth quarter of 2002 due to conservative consideration at that time. The Company is fully committed to pursue collection of the full amount owing,” said Dr. Wick. Subsequent to the quarter end, the Board of Directors removed Dr. Liu as Chairman of the Board of Directors.

“During the third quarter of 2003, the Company completed an upgrade of its current production facility in Nanjing, China, doubling the production capacity of its roller bottle technology to fulfill demand from China and other developing markets.” said, Dr. Wick, “In addition, subsequent to quarter-end, the Company signed an agreement with a European biotechnology company specialized in research and development of recombinant human proteins to develop a high yield and proprietary EPO cell-line and production process technology which will be the cornerstone of our entry strategy to the European market upon the expiry of the related patents in 2004.”

Top Dragon Pharma Steroids

Dragon Pharma is manufacturing a wide range of steroids Buy TriTren 150.

No Tags

1578 total views, 2 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics